Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Duchesnay Launches New Formulation of its Pregvit® and Pregvit® Folic 5 Prenatal Vitamins

Duchesnay inc.
Posted on: 04 Oct 16

Canada NewsWire

BLAINVILLE, QC, Oct. 4, 2016

BLAINVILLE, QC, Oct. 4, 2016 /CNW Telbec/ - Duchesnay Inc. is proud to announce the recent modification of the formulation and packaging of its Pregvit® and Pregvit® Folic 5 prenatal vitamins, the only prescription multivitamin- mineral supplements available in Canada. The new formulations are higher in vitamin D, a nutrient that promotes healthy skeletal development and helps maintain bone integrity in both mother and foetus.

The formulation of Pregvit® and Pregvit® Folic 5 was changed based on Health Canada's current recommendation of a dietary reference intake of 600 IU (International Units) of vitamin D per day during pregnancy and lactation. Vitamin D content was increased from 250 to 600 IU.

The new formulations of Pregvit®and Pregvit® Folic 5, in their new packaging, are now available from your pharmacist. They do not contain lactose, gluten or tartrazine. Both products are also certified halal and kosher/kosher for Passover by recognized authorities as mentioned in the booklet. 

Product monograph are available at You can also contact Duchesnay's Medical Information Service at 1 888-666-0611 for more information.

About Pregvit® and Pregvit® Folic 5
Pregvit® and Pregvit® Folic 5 prenatal multivitamins offer a unique formulation and twice-daily dosing (a pink tablet in the morning and a blue tablet at night), whose primary purpose is to optimize the absorption of the most important nutrients prior to conception and throughout pregnancy and lactation. The formulation reduces side effects, such as gastro-intestinal issues, nausea and constipation. They do not contain lactose, gluten or tartrazine. Both products are also certified halal and kosher/kosher for Passover by recognized authorities as mentioned in the booklet. 

Pregvit® Folic 5 was designed for women at high risk or who have had a previous pregnancy affected by a neural tube defect, those with a family history of neural tube defects, those who have diabetes or malabsorption disorders (e.g. inflammatory bowel disease), those who take anticonvulsive medications (e.g. valproic acid, carbamazepine) or medications known to decrease folate levels (e.g. methotrexate), or those who, according to their healthcare professional, require a higher dose of Folic acid.

Pregvit® and Pregvit® Folic 5 are available by prescription only in Canada. Women who are planning to become pregnant are advised to speak to their healthcare professional to determine which product best meets their needs.

About Duchesnay
Duchesnay Inc. is a unique Quebec-based pharmaceutical company dedicated to the health and quality of life of pregnant women and their unborn babies. To that end, the company works to advance maternal-fetal medicine to reduce the risks of birth defects and to develop safe and effective pharmaceutical solutions for use during pregnancy and breastfeeding. Duchesnay's product line includes Diclectin for the management of nausea and vomiting of pregnancy (NVP).  In order to improve women's quality of life at every stage, Duchesnay also offers therapeutic options in obstetrics and gynecology, such as LadySystem® therapy to treat stress urinary incontinence, Proctofoam® for the temporary relief of discomfort due to hemorrhoids, and Prevegyne® to ease the symptoms of non-specific vaginitis/bacterial vaginosis. To learn more about Duchesnay, please visit us at


SOURCE Duchesnay inc.

PR Newswire

Last updated on: 04/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.